A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2124 participants.
Also called NCT01830543
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,124 participants
- Registry
-
NCT01830543 -
2012-001491-11
-
- Other papers using this trial's data
- Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
- Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial
- Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
- Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
- Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, South Africa, South Korea, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01830543. Randomized; no masking; primary purpose treatment. Start 2013-05-10 (actual); primary completion 2016-07-28 (actual). Results posted on 2017-07-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- Acronym
- PIONEER AF-PCI
- Condition
- Atrial Fibrillation
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- rivaroxaban 2.5 mg
- Intervention (Drug)
- rivaroxaban 15 mg
- Intervention (Drug)
- rivaroxaban 10 mg
- Intervention (Drug)
- aspirin (ASA)
- Intervention (Drug)
- vitamin K antagonist (VKA)
- Intervention (Drug)
- clopidogrel
- Intervention (Drug)
- prasugrel
- Intervention (Drug)
- ticagrelor
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct01830543- Content hash
42f17ac0bfde9ddd8359bdd53fc6ee813eadb0120bfadfa2fc95db9fde2bc4a1